New Risk • Jul 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (₹565.9m market cap, or US$5.96m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years. Duyuru • May 11
Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026 Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026 New Risk • Mar 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results. Duyuru • Feb 05
Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026 Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Jan 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results. Duyuru • Nov 05
Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025 Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹32.83, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 394% over the past three years. Duyuru • Sep 05
Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025 Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025, at 13:00 Indian Standard Time. Duyuru • Aug 06
Bacil Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025 Bacil Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Board Change • Aug 01
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Non-Executive Independent Director Avani Godhaniya is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Duyuru • May 18
Bacil Pharma Limited to Report Q4, 2025 Results on May 26, 2025 Bacil Pharma Limited announced that they will report Q4, 2025 results on May 26, 2025 New Risk • May 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 144% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹594.2m market cap, or US$7.03m). Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹12m sold). Recent Insider Transactions • Mar 25
Executive Director recently sold ₹7.9m worth of stock On the 21st of March, Prakash Shah sold around 208k shares on-market at roughly ₹38.00 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹16m more than they bought in the last 12 months. Recent Insider Transactions • Mar 12
Executive Director recently sold ₹4.1m worth of stock On the 10th of March, Prakash Shah sold around 115k shares on-market at roughly ₹35.89 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.1m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹47.88, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 404% over the past three years. Duyuru • Jan 13
Bacil Pharma Limited to Report Q3, 2025 Results on Jan 21, 2025 Bacil Pharma Limited announced that they will report Q3, 2025 results on Jan 21, 2025 Duyuru • Oct 16
Bacil Pharma Limited to Report Q2, 2025 Results on Oct 23, 2024 Bacil Pharma Limited announced that they will report Q2, 2025 results on Oct 23, 2024 Recent Insider Transactions • Sep 24
Executive Director recently sold ₹4.0m worth of stock On the 20th of September, Prakash Shah sold around 157k shares on-market at roughly ₹25.63 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Duyuru • Sep 10
Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024 Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024, at 10:00 Indian Standard Time. Location: 71, laxmi building, 4th floor, sir p m road, fort, mumbai-400001, mumbai India Board Change • Sep 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent Non-Executive Director Lalit Jain was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Aug 31
Bacil Pharma Limited Announces Resignation Suman Prakash Shah as Non-Executive Director Bacil Pharma Limited announced that at the board meeting held on August 31, 2024, approved resignation of Mrs. Suman Prakash Shah as Non-Executive Director of the Company with effect from August 31, 2024 due to pre-occupancy in other assignments and personal. reasons. Names of Listed Entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any. 1. Directorship -Sanmitra Commercia Limited 2. Membership/Chairmanship in Board Committees- NIL. Duyuru • Aug 08
Bacil Pharma Limited to Report Q1, 2025 Results on Aug 14, 2024 Bacil Pharma Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Duyuru • May 17
Bacil Pharma Limited to Report Q4, 2024 Results on May 21, 2024 Bacil Pharma Limited announced that they will report Q4, 2024 results on May 21, 2024 New Risk • Nov 13
New major risk - Revenue and earnings growth Earnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 0.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₹46.8m market cap, or US$561.2k). Duyuru • Nov 04
Bacil Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023 Bacil Pharma Limited announced that they will report Q2, 2024 results on Nov 10, 2023 Duyuru • Sep 15
Bacil Pharma Limited Appoints Mrs. Bhavana Tak as Company Secretary and Compliance Officer Board of Directors of Bacil Pharma Limited at their meeting held on 14 th September, 2023 transacted the following Business: Considered and approved appointment of Mrs. Bhavana Tak (ACS No- A71532) as Company Secretary and Compliance Officer of the Company based on recommendation by Nomination and Remuneration Committee. Mrs. Bhavana Tak is a Qualified Company Secretary and having work Experience undera PCS Firm. Duyuru • Aug 25
Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023 Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023, at 14:00 Indian Standard Time. Location: 71, Laxmi Building, 4th Floor, Sir P. M. Road Fort Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company as at 31st March, 2023 and Reports of the Directors' and Auditor's thereon; to appoint a Director in place of Mr. Prakash Bhoorchand Shah who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment; and to consider other matter. Duyuru • Aug 08
Bacil Pharma Limited to Report Q1, 2024 Results on Aug 14, 2023 Bacil Pharma Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Duyuru • Feb 03
Bacil Pharma Limited to Report Q3, 2023 Results on Feb 11, 2023 Bacil Pharma Limited announced that they will report Q3, 2023 results on Feb 11, 2023 Board Change • Oct 31
High number of new directors Non-Executive & Non-Independent Director Suman Shah was the last director to join the board, commencing their role in 2022. Duyuru • Sep 30
Bacil Pharma Limited Appoints Suman Shah as Non-Executive Non- Independent Director Bacil Pharma Limited appointed Suman Shah (DIN: 01764668), as Non-Executive Non- Independent Director of the Company at its AGM held on September 29, 2022. Duyuru • Sep 02
Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022 Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022. Agenda: To consider and approve re-appointment of M/s Laxmikant Kabra & Co, LLP as Statutory Auditors of the Company for the second term of Five Years from Financial Year 2022-23 up to Financial Year 2026-27; to consider and approve appointment of Mrs. Suman Shah as Non-Executive Non-Independent Director of the Company; and to consider other matters. Duyuru • May 23
Bacil Pharma Limited to Report Q4, 2022 Results on May 30, 2022 Bacil Pharma Limited announced that they will report Q4, 2022 results on May 30, 2022 Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Feb 06
Bacil Pharma Limited to Report Q3, 2022 Results on Feb 14, 2022 Bacil Pharma Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Board Change • Sep 13
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Lalit Jain was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Mar 05
New 90-day low: ₹4.53 The company is down 19% from its price of ₹5.60 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Duyuru • Feb 06
Bacil Pharma Limited to Report Q3, 2021 Results on Feb 13, 2021 Bacil Pharma Limited announced that they will report Q3, 2021 results on Feb 13, 2021 Is New 90 Day High Low • Dec 31
New 90-day low: ₹4.72 The company is down 9.0% from its price of ₹5.20 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Duyuru • Oct 20
Bacil Pharma Limited Announces Appointment of Vaishali Vaghasiya as Company Secretary and Compliance Officer Bacil Pharma Limited announced that Ms. Vaishali Vaghasiya (A-60980) a qualified member of Institute of Company Secretary of India is been appointed as Company Secretary and Compliance Officer of the company with effect from 19 October, 2020, pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015. Is New 90 Day High Low • Sep 22
New 90-day high: ₹3.74 The company is up 44% from its price of ₹2.60 on 24 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period. Duyuru • Sep 12
Bacil Pharma Limited to Report Q1, 2021 Results on Sep 15, 2020 Bacil Pharma Limited announced that they will report Q1, 2021 results on Sep 15, 2020 Duyuru • Jul 26
Bacil Pharma Limited to Report Q4, 2020 Results on Jul 30, 2020 Bacil Pharma Limited announced that they will report Q4, 2020 results on Jul 30, 2020 
